Our team
Gottfried Wilhelm Leibniz Universitaet Hannover
The Leibniz University of Hannover (LUH) is coordinator of the SMARTER project. The institute of technical chemistry (TCI) of the LUH is an applied research institute with leading expertise in bioprocess engineering and bioprocess sensor development. TCI have a far-reaching expertise in developing 2D fluorescence sensors to detect online and inline potential biomarkers in cell culture bioreactor. Fluorescence spectroscopy is a very sensitive tool for monitoring biomolecules even at low concentrations. The multivariate data analysis allows far-reaching insight into the cell state. The development of a specific fluorescence sensor for T-cell production is of greatest interest to enable monitored and controlled CGT production.

Meet the team
Cell Therapy Catapult Limited
The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. As part of the SMARTER project, the Cell and Gene Therapy Catapult’s main tasks include leading consortium activities under ‘WP3 Raman Spectroscopy Sensor Development’ and ‘WP5 Proof of Concept of Advanced Process Control’. All CGT Catapult activities will be undertaken in CGT Catapult’s world-leading development laboratories based in London, UK.
The Cell and Gene Therapy Catapult works with Innovate UK. For more information, please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

Meet the team
Achilles Therapeutics UK Limited
Achilles Therapeutics is a biopharmaceutical company developing precision T cell therapies that target clonal neoantigens. Neoantigens are protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumor evolution which allows us to leverage our bioinformatics platform – powered by artificial intelligence (AI) – to identify ‘clonal’ neoantigens that arise early in cancer development and are retained as each tumor continues to grow and mutate. By directing T cell therapies against clonal neoantigens, which are present on all cancer cells and are completely absent from normal cells, we can for the first time target every cancer cell without attacking healthy tissue.

Meet the team
Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana
The Biomarkers and Precision Medicine Unit (BPMU) at the Health Research Institute of the Hospital La Fe (HULAFE) (Valencia, Spain) joins clinicians and basic researchers who share the motivation to undertake bench-to-bedside translational research with the goal of promoting the use of metabolomics in precision medicine. The BPMU has strong expertise in the use and development of mass-spectrometry-based metabolomics approaches to study cancer and immune cell metabolism as a strategy to discover new therapeutic targets, metabolic interventions and biomarkers to improve lung cancer treatment. BPMU-HULAFE’s main tasks within the project include the comprehensive metabolomics analysis of spent media samples to identify biomarkers that could be used for real-time monitoring of T cell expansion and activity.
